Modular Medical, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Modular Medical, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $0 | Jun 29, 2018 |
| FY2017 | Jun 30, 2017 | $0 | Oct 11, 2017 |
| FY2018 | Mar 31, 2017 | $0 | Jun 29, 2018 |
| FY2017 | Jun 30, 2016 | $0 | Oct 11, 2017 |
| FY2016 | Jun 30, 2015 | $0 | Sep 26, 2016 |
| FY2015 | Jun 30, 2014 | $0 | Sep 30, 2015 |
| FY2014 | Jun 30, 2013 | $0 | Sep 23, 2014 |
| FY2013 | Jun 30, 2012 | $0 | Sep 3, 2013 |
| FY2012 | Jun 30, 2011 | $0 | Sep 12, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Jun 30, 2016 | $0 | Sep 26, 2016 |
| FY2016 | Jun 30, 2015 | $0 | Sep 26, 2016 |
| FY2015 | Jun 30, 2014 | $0 | Sep 30, 2015 |
| FY2014 | Jun 30, 2013 | $0 | Sep 23, 2014 |
| FY2013 | Jun 30, 2012 | $0 | Sep 3, 2013 |
| FY2012 | Jun 30, 2011 | $0 | Sep 12, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($18.82M) | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | ($17.47M) | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | ($13.88M) | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | ($18.63M) | Jun 26, 2023 |
| FY2022 | Mar 31, 2021 | ($7.38M) | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | ($5.32M) | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | ($2.54M) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($659.2K) | Jun 27, 2019 |
| FY2017 | Jun 30, 2017 | ($106.6K) | Oct 11, 2017 |
| FY2018 | Mar 31, 2017 | ($29.3K) | Jun 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($19.05M) | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | ($17.53M) | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | ($13.88M) | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | ($14.93M) | Jun 26, 2023 |
| FY2022 | Mar 31, 2021 | ($7.34M) | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | ($5.35M) | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | ($2.58M) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($666.2K) | Jun 27, 2019 |
| FY2017 | Jun 30, 2017 | ($91.1K) | Oct 11, 2017 |
| FY2018 | Mar 31, 2017 | ($29.4K) | Jun 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $14.70M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $12.88M | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | $9.06M | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | $7.73M | Jun 26, 2023 |
| FY2022 | Mar 31, 2021 | $4.08M | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $3.03M | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $1.88M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $332.6K | Jun 27, 2019 |
| FY2018 | Mar 31, 2017 | $0 | Jun 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($15.72M) | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | ($13.95M) | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | ($11.01M) | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | ($10.26M) | Jun 26, 2023 |
| FY2022 | Mar 31, 2021 | ($5.91M) | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | ($4.09M) | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | ($1.81M) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($791.1K) | Jun 27, 2019 |
| FY2017 | Jun 30, 2017 | ($94.8K) | Oct 11, 2017 |
| FY2018 | Mar 31, 2017 | ($21.1K) | Jun 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.49M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $1.70M | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | $1.64M | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | $54.8K | Jun 26, 2023 |
| FY2022 | Mar 31, 2021 | $109.7K | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $260.8K | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $77.1K | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $15.1K | Jun 27, 2019 |
| FY2018 | Mar 31, 2017 | $0 | Jun 29, 2018 |
| FY2014 | Jun 30, 2014 | $0 | Sep 23, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $18.74M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $13.81M | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | $7.25M | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | $9.85M | Jun 26, 2023 |
| FY2022 | Mar 31, 2021 | $2.25M | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $3.86M | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $6.65M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $4.33M | Jun 27, 2019 |
| FY2017 | Jun 30, 2017 | $1.37M | Oct 11, 2017 |
| FY2018 | Mar 31, 2017 | $392.3K | Jun 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.66M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $2.27M | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | $2.17M | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | $1.01M | Jun 26, 2023 |
| FY2022 | Mar 31, 2021 | $3.52M | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $980.1K | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $178.7K | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $15.5K | Jun 27, 2019 |
| FY2018 | Mar 31, 2017 | $29.7K | Jun 29, 2018 |
| FY2016 | Jun 30, 2016 | $193.8K | Sep 26, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $17.08M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $11.54M | Jun 20, 2025 |
| FY2025 | Mar 31, 2023 | $5.08M | Jun 20, 2025 |
| FY2024 | Mar 31, 2022 | $8.84M | Jun 21, 2024 |
| FY2023 | Mar 31, 2021 | ($1.28M) | Jun 26, 2023 |
| FY2022 | Mar 31, 2020 | $2.88M | Jun 28, 2022 |
| FY2021 | Mar 31, 2019 | $6.47M | Jun 29, 2021 |
| FY2020 | Mar 31, 2018 | $4.32M | Jun 29, 2020 |
| FY2017 | Jun 30, 2017 | $1.30M | Oct 11, 2017 |
| FY2019 | Mar 31, 2017 | $362.6K | Jun 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($84.75M) | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | ($65.93M) | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | ($48.46M) | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | ($34.58M) | Jun 26, 2023 |
| FY2022 | Mar 31, 2021 | ($15.95M) | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | ($8.57M) | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | ($3.25M) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($708.7K) | Jun 27, 2019 |
| FY2017 | Jun 30, 2017 | ($384.4K) | Oct 11, 2017 |
| FY2018 | Mar 31, 2017 | ($49.4K) | Jun 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $13.10M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $9.23M | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | $3.80M | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | $9.08M | Jun 26, 2023 |
| FY2022 | Mar 31, 2021 | $1.47M | Jun 28, 2022 |
| FY2022 | Mar 31, 2020 | $3.12M | Jun 28, 2022 |
| FY2021 | Mar 31, 2019 | $6.55M | Jun 29, 2021 |
| FY2020 | Mar 31, 2018 | $4.30M | Jun 29, 2020 |
| FY2017 | Jun 30, 2017 | $1.37M | Oct 11, 2017 |
| FY2019 | Mar 31, 2017 | $392.0K | Jun 27, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | (1) | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | (2) | Jun 26, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | (1) | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | (2) | Jun 26, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 53.71M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | 32.46M | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | 10.95M | Jun 21, 2024 |
| FY2023 | Mar 31, 2022 | 10.46M | Jun 26, 2023 |
| FY2022 | Mar 31, 2021 | 6.30M | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | 17.87M | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | 17.84M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | 15.98M | Jun 27, 2019 |
| FY2017 | Jun 30, 2017 | 3.50M | Oct 11, 2017 |
| FY2018 | Mar 31, 2017 | 7.58M | Jun 29, 2018 |